Tandem Diabetes Care (Nasdaq:TNDM) announced preliminary fourth-quarter results and offered expectations for the coming year.
San Diego-based Tandem expects sales to total $221 million, coming in $11 million higher than the same quarter last year. Wall Street analysts expect $221.6 million in revenues. The automated insulin delivery technology developer noted that its adjusted sales rise to $224 million for the quarter. That total includes the impact of its Tandem Choice Program which allows users to switch to a new pump model when available.
Get the full story at our sister site, Drug Delivery Business News.